ARAV Stock Overview
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Aravive, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.04 |
| 52 Week High | US$2.46 |
| 52 Week Low | US$0.04 |
| Beta | 2.19 |
| 1 Month Change | -67.58% |
| 3 Month Change | -69.30% |
| 1 Year Change | -97.63% |
| 3 Year Change | -99.22% |
| 5 Year Change | -99.06% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Apr 26
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Sep 03Aravive Q2 GAAP EPS misses, revenue beats
Aug 11Aravive appoints Robert Geller as CMO
Jul 05We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully
May 15Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Nov 06Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Jun 25Aravive EPS beats by $0.01, misses on revenue
May 06Aravive shares rise after dosing first patient in late-stage ovarian cancer study
Apr 27Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?
Mar 18Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Feb 09
Aravive: Pipeline-In-A-Pill In Oncology
Dec 28Aravive (ARAV) Investor Presentation - Slideshow
Dec 04Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative
Nov 19Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China
Nov 10Shareholder Returns
| ARAV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -17.3% | 4.7% | 0.7% |
| 1Y | -97.6% | 2.7% | 23.9% |
Return vs Industry: ARAV underperformed the US Biotechs industry which returned 6.5% over the past year.
Return vs Market: ARAV underperformed the US Market which returned 17.6% over the past year.
Price Volatility
| ARAV volatility | |
|---|---|
| ARAV Average Weekly Movement | 19.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARAV's share price has been volatile over the past 3 months.
Volatility Over Time: ARAV's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 23 | n/a | aravive.com |
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway.
Aravive, Inc. Fundamentals Summary
| ARAV fundamental statistics | |
|---|---|
| Market cap | US$2.95m |
| Earnings (TTM) | -US$39.85m |
| Revenue (TTM) | US$6.99m |
0.4x
P/S Ratio-0.1x
P/E RatioIs ARAV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARAV income statement (TTM) | |
|---|---|
| Revenue | US$6.99m |
| Cost of Revenue | US$53.39m |
| Gross Profit | -US$46.39m |
| Other Expenses | -US$6.55m |
| Earnings | -US$39.85m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | -663.34% |
| Net Profit Margin | -569.73% |
| Debt/Equity Ratio | 0% |
How did ARAV perform over the long term?
See historical performance and comparison